Viewing nowAmicabon Tablet (Sodium Ibandronate Monohydrate)
Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Huons Co., Ltd.

MFDS item code 201205930 · Approved 2012.06.26
Treatment of osteoporosis in postmenopausal women
This medication is used for the treatment of osteoporosis in postmenopausal women. It helps increase bone mineral density, reducing the risk of fractures, and improves the weakening of bones due to osteoporosis. Treating osteoporosis can maintain the bone health of the patients and enhance their quality of life.
Take 1 tablet once a month, regularly on the same day each month in the morning, with plenty of water, at least 1 hour before consuming food, beverages (other than water), or other oral medicines or dietary supplements (including calcium): - Swallow this medicine with a sufficient amount of water (180-240ml) while standing or sitting upright, and do not lie down for 60 minutes after taking it. - Mineral water may reduce the absorption of this medicine; therefore, take it with plain water. - Do not chew or suck the tablet, to avoid esophageal ulcers. If the patient forgets to take the medicine on the scheduled dosing day - If 8 days or more remain until the next scheduled dose, take 1 tablet the morning after realizing that the dose was missed, and thereafter take 1 tablet each month on the previously scheduled dosing day. - If 7 days or less remain until the next scheduled dose, take 1 tablet on the next scheduled dosing day, and thereafter continue taking 1 tablet each month on the previously scheduled dosing day. - Do not take 2 tablets in the same week. Patients with inadequate dietary intake should supplement with calcium or vitamin D. Patients with hepatic impairment No dose adjustment is required. Patients with renal impairment No dose adjustment is required for patients with mild or moderate renal impairment and a creatinine clearance of 30mL/min or greater. Use of this medicine is not recommended in patients with a creatinine clearance below 30mL/min because clinical experience is insufficient. Elderly patients No dose adjustment is required.
Efficacy and safety in children 18 years of age or younger have not been studied.
This medication should not be used in certain patients. It should not be administered to patients with allergies to this medication or any of its components, patients with untreated hypocalcemia, patients unable to sit or stand upright for more than 60 minutes, patients with esophageal disorders, and patients with lactose intolerance or related genetic disorders. It should be used cautiously in patients with severe renal failure. This medication can irritate the gastrointestinal tract, potentially leading to symptoms such as dyspepsia, nausea, abdominal pain, and diarrhea. Additionally, symptoms such as headache, fatigue, myalgia, arthralgia, and rash have also been reported. In rare cases, serious side effects such as eye inflammation or osteonecrosis of the jaw may occur in some patients. Before taking this medication, it is important to treat hypocalcemia or bone and mineral metabolic disorders, and to ensure adequate intake of calcium and vitamin D. While taking the medication, patients must remain sitting or standing upright for at least 60 minutes and should follow the correct administration procedures to minimize esophageal irritation. Moreover, patients must avoid consuming food or products containing calcium, aluminum, magnesium, or iron within one hour of taking this medication. Caution should be observed when taking this medication alongside non-steroidal anti-inflammatory drugs due to the risk of gastrointestinal irritation. Patients at risk of osteonecrosis of the jaw should undergo dental examinations before beginning treatment and should avoid excessive dental procedures during treatment. This medication is not safe for use in pregnant or nursing women. Safety and efficacy have not been established in children under 18 years old. In case of overdose, gastrointestinal disturbances and hypocalcemia may occur, and immediate consultation with a healthcare provider is advised. Finally, this medication should be kept out of reach of children, and expired medications should be disposed of safely.
Dyspepsia, nausea, abdominal pain, diarrhea, bloating, gastroesophageal reflux disease, headache, influenza-like illness, fatigue, myalgia, arthralgia, rash, esophagitis, muscle cramps, musculoskeletal pain, musculoskeletal stiffness, dysphagia, vomiting, esophageal ulcer, esophageal stricture, dizziness, low back pain, duodenitis, hypersensitivity reaction, angioedema, facial edema, urticaria, uveitis, scleritis, osteonecrosis of the jaw and external auditory canal, anaphylaxis, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical femoral fracture, subtrochanteric femoral fracture, ocular paresthesia, myasthenia, pruritus
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. The recommended storage temperature is between 1 to 30 degrees Celsius.
White to almost white, rectangular film-coated tablet
1 tablet (1 tablet PTP x 1)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowIbandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Huons Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.